Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients

Guideline for the classification of the acute emetogenic potential of antineoplastic medication... This guideline provides clinicians caring for children with an approach to assessing the acute emetogenic potential of antineoplastic therapies. It was developed by an international, inter‐professional panel of clinicians and researchers using AGREE and CAN‐ADAPTE methods. The emetogenicity of antineoplastic agents was evaluated and ranked as high, moderate, low, or minimal. The emetogenicity of multiple‐agent and multiple‐day antineoplastic therapy was also classified. Gaps in the evidence used to underpin the guideline recommendations were identified. The contribution of this guideline to the prevention of antineoplastic‐induced nausea and vomiting in individual children about to receive antineoplastic therapy requires prospective evaluation. Pediatr Blood Cancer 2011; 57: 191–198. © 2011 Wiley‐Liss, Inc. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pediatric Blood & Cancer Wiley

Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients

Loading next page...
 
/lp/wiley/guideline-for-the-classification-of-the-acute-emetogenic-potential-of-g0I6QA63MN

References (45)

Publisher
Wiley
Copyright
Copyright © 2011 Wiley‐Liss, Inc.
ISSN
1545-5009
eISSN
1545-5017
DOI
10.1002/pbc.23114
pmid
21465637
Publisher site
See Article on Publisher Site

Abstract

This guideline provides clinicians caring for children with an approach to assessing the acute emetogenic potential of antineoplastic therapies. It was developed by an international, inter‐professional panel of clinicians and researchers using AGREE and CAN‐ADAPTE methods. The emetogenicity of antineoplastic agents was evaluated and ranked as high, moderate, low, or minimal. The emetogenicity of multiple‐agent and multiple‐day antineoplastic therapy was also classified. Gaps in the evidence used to underpin the guideline recommendations were identified. The contribution of this guideline to the prevention of antineoplastic‐induced nausea and vomiting in individual children about to receive antineoplastic therapy requires prospective evaluation. Pediatr Blood Cancer 2011; 57: 191–198. © 2011 Wiley‐Liss, Inc.

Journal

Pediatric Blood & CancerWiley

Published: Aug 1, 2011

There are no references for this article.